Discover key insights from Embecta's Q2 2025 earnings call. Learn about revenue forecasts, cost-saving initiatives, product strategies & market dynamics.

facilitates adherence to intensive insulin therapy regimens, helps to improve lifestyle flexibility and reduces injection pain compared with conventional syringe-based regimens. Together these ...

Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ETCompany ParticipantsDev Kurdikar - President & CEOJake Elguicze ...

The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4 ...

72 hr Manufacturer Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi ...

Operator: Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants ...

The global Injectable Drug Delivery Market, valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 ...

In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

In a study published in eClinicalMedicine, researchers at the German Diabetes Center (DDZ) show that automated insulin ...

Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.

Welcome, ladies and gentlemen, to Embecta Corp's Fiscal Second Quarter 2025 Earnings Conference Call. (Operator Instructions) Please note that this conference call is being recorded and a replay will ...